Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Phase 1

Completed

• Conditions: Multiple Myeloma

• Registration Number: NCT00116441
• Lead Sponsor: Cell Genesys

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.

Detailed Description

Not available

Study Timeline

• Study Start: 2000-10
• Study Completion: 2004-10
• Study First Submitted: 2005-06-29
• Study First Submitted QC: 2005-06-29
• Study First Posted: 2005-06-30
• Status Verified: 2007-12
• Last Update Submitted: 2007-12-18
• Last Update Posted: 2007-12-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• De novo multiple myeloma
• ECOG 0-2
• No serious co-morbid illnesses and adequate organ function
• > 4 weeks from systemic steroids

Exclusion Criteria

• No existing secondary malignancies and no history of secondary malignancies in the past 5 years
• No active autoimmune disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Multiple myeloma

Trial Locations

Locations (1)

Johns Hopkins University; 🇺🇸 Baltimore, Maryland, United States